Bill Gates regains world's richest man title: Forbes

March 4, 2014

Bill_Gates_regainsNew York, Mar 4: Microsoft co-founder Bill Gates has regained the title of the world's richest man in the Forbes magazine's annual billionaire list that includes 56 India based billionaires led by RIL Chairman Mukesh Ambani.

Gates is back at the top spot after a four-year hiatus, reclaiming the title of world's richest person from Mexican telecom mogul Carlos Slim Helu, who had ranked number 1 for the previous four years.

Gates, whose fortune rose by USD 9 billion in the past year to USD 76 billion, has held the top spot for 15 of the past 20 years.

"After years focused on his philanthropy, Gates plans to spend more of his time working with product managers at Microsoft as rivals like Google and Apple continue to outshine the company in the market," Forbes said.

With a networth of USD 18.6 billion, Reliance Industries Ltd (RIL) chief Mukesh Ambani leads the pack of 56 billionaires based in India featured on the list.

His younger brother Anil Ambani is ranked 281st on the list with a net worth of USD 5 billion.

However, Forbes said the richest Indian person has seen "precipitous decline" in his fortune since 2008 when his networth was USD 43 billion and he when was the world's fifth richest person.

"Regardless he remains India's richest person and is still bullish; says he plans to invest USD 25 billion in his businesses over the next 2 years," Forbes said.

The magazine also referred to accusations of wrongdoing made against Reliance by Aam Admi Party founder Arvind Kejriwal, who had recently alleged that Ambani is "running the government".

The other Indian billionaires in the list are ArcelorMittal Chairman and CEO Lakshmi Mittal who is ranked 52nd with a networth of USD 16.7 billion, Wipro Chairman Azim Premji ranked 61st with USD 15.3 billion, founder of Sun Pharma Dilip Shanghvi ranked 82nd with USD 12.8 billion, HCL co-founder Shiv Nadar is ranked 102nd and has a net worth of USD 11.1 billion. Hinduja brothers came in at the 122nd with USD 10 billion.

Birla group chief Kumar Birla is ranked 191st and has a networth of USD 7 billion, Forbes said the ranks of the world's billionaires continued to scale new heights and stretched to new corners of the world.

The list has 1,645 billionaires with an aggregate net worth of USD 6.4 trillion, up from USD 5.4 trillion a year ago. The list features a record 268 new ten-figure fortunes, including 42 new women billionaires.

In total, there are 172 women on the list, more than ever before and up from 138 last year.

The year's biggest dollar gainer was Facebook's Mark Zuckerberg, whose fortune jumped USD 15.2 billion, to USD 28.5 billion, as shares of his social network soared.

Facebook's COO, Sheryl Sandberg, joins the ranks for the first time, as does the company's longtime vice president Jeff Rothschild.

Also, thanks to a USD 19 billion deal with Facebook, WhatsApp founders Jan Koum and Brian Acton join the ranks of Silicon Valley's wealthiest for the first time. They are 4 of 26 newcomers whose fortunes come from technology, 10 of whom are American, including Dropbox CEO Drew Houston and Workday cofounder Aneel Bhusri.

The US once again leads the world with 492 billionaires, followed by China with 152 and Russia with 111. The list has new billionaires from Algeria, Lithuania, Tanzania and Uganda.

The other Indian billionaires on the list are Indian telecom tycoon Sunil Mittal, who is ranked 244th and has a networth of USD 5.7 billion. Forbes said Mittal saw his wealth decline by USD 1.1 billion despite big

moves to cement his Bharti Airtel's position as India's biggest mobile operator which has 200 million domestic customers.

Savitri Jindal and family, is on the 295th spot tied with vaccine billionaire Cyrus Poonawala and Essar group's Shashi and Ravi Ruia, India's richest banker Uday Kotak is ranked 396th followed by Godrej group chief Adi Godrej (446), real estate mogul Kush Pal Singh (551), Hero group founder Brijmohan Lall Munjal (731), brothers Malvinder and Shivinder Singh, who control hospital chain Fortis Healthcare (828).

Sun TV Network's Kalanithi Maran (796), Indian two wheeler tycoon Rahul Bajaj (973), Infosys executive chairman N.R. Narayana Murthy (1046) and former chief executive of Infosys Nandan Nilekani (1210) are also in the list.

In the top-ten are Oracle founder Larry Ellison at the 5th spot with USD 48 billion, Koch Industries CEO Charles Koch at 6th with USD 40 billion, and Chairman and CEO, Arvest Bank Group Jim Walton on the 10th rank with USD 34.7 billion.

For the 28th annual billionaire list Forbes, compiled networth by valuing individuals' assets–including stakes in public and private companies, real estate, yachts, art and cash–and take into account estimates of debt.

Spanish clothing retailer Amancio Ortega (best known for the Zara fashion chain) retains 3rd rank for the second year in a row, extending his lead over Warren Buffett, who is again on 4th spot.

American gambling tycoon Sheldon Adelson, who added USD 11.5 billion to his pile, makes it back into the top ten for the first time since 2007.

Roughly two-thirds of the billionaires built their own fortunes, 13 per cent inherited them and 21 per cent have been adding on to fortunes they received.

Other notable newcomers include World Wrestling Entertainment CEO Vince McMahon, fashion king Michael Kors and Denise Coates of UK online betting firm Bet365.

Forbes said not all countries–or tycoons–had good years.

Turkey lost 19 billionaires due to soaring inflation, a sagging stock market and a declining value in its currency.

Indonesia, whose currency tumbled 20 per cent against the dollar, now has eight fewer ten-figure fortunes. Altogether 100 people dropped out of the ranks, while another 16 passed away.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 22,2020

A team of scientists has produced first open source all-atom models of full-length COVID-19 Spike protein that facilitates viral entry into host cells – a discovery that can facilitate a faster vaccine and antiviral drug development.

The group from Seoul National University in South Korea, University of Cambridge in the UK and Lehigh University in the US produced the first open-source all-atom models of a full-length S protein.

The researchers say this is of particular importance because the S protein plays a central role in viral entry into cells, making it a main target for vaccine and antiviral drug development.

"Our models are the first full-length SARS-CoV-2 spike (S) protein models that are available to other scientists," said Wonpil Im, a professor in Lehigh University.

"Our team spent days and nights to build these models very carefully from the known cryo-EM structure portions. Modeling was very challenging because there were many regions where simple modeling failed to provide high-quality models," he wrote in a paper published in The Journal of Physical Chemistry B.

Scientists can use the models to conduct innovative and novel simulation research for the prevention and treatment of Covid-19.

Though the coronavirus uses many different proteins to replicate and invade cells, the Spike protein is the major surface protein that it uses to bind to a receptor.

The total number of global COVID-19 cases was nearing 9 million, while the deaths have increased to over 467,000, according to the Johns Hopkins University.

With 2,279,306 cases and 119,967 deaths, the US continues with the world's highest number of COVID-19 infections and fatalities, according to the CSSE.

Brazil comes in the second place with 1,083,341 infections and 50,591 deaths.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
March 27,2020

New Delhi, Mar 27: The Centre has restricted sale and distribution of "hydroxychloroquine" declaring it as an essential drug to treat the COVID-19 patients and meet the requirements of emergency arising due to the pandemic.

The Ministry of Health and Family Welfare on Thursday made the announcement making it clear that the order "shall come into force on the date of its publication in the official Gazette".

In the order, the government declared that the Central government is "satisfied that the drug hydroxychloroquine is essential to meet the requirements of emergency arising due to pandemic COVID-19 and in the public interest, it is necessary and expedient to regulate and restrict the sale and distribution of the drug 'hydroxychloroquine' and preparation based thereon for preventing their misuse".

"Now, therefore, in exercise of the powers conferred by Section 26B of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central government hereby directs that sale by retail of any preparation containing the drug Hydroxychloroquine shall be in accordance with the conditions for sale of drugs specified in Schedule H1 to the Drugs and Cosmetics Rules, 1945."

The order came at a time when the novel coronavirus claimed 16 lives and infected over 600 people across India.

The announcement regarding ban of sale and distribution of the drug was made by the government earlier but it issued an official Gazette notification on Thursday signalling that hydroxychloroquine -- an anti-Malaria drug -- will work as a medicine for treating coronavirus infected patients as well.

Recently, the national task force for COVID-19 constituted by Indian Council for Medical Research (ICMR) has recommended hydroxy-chloroquine as a preventive medication.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 13,2020

California, May 13: A fasting-mimicking diet could be more effective at treating some types of cancer when combined with vitamin C, suggests a new study conducted by the scientists from USC and the IFOM Cancer Institute in Milan.

In studies on mice, researchers found that the combination delayed tumour progression in multiple mouse models of colorectal cancer; in some mice, it caused disease regression. The results were published in the journal Nature Communications.

"For the first time, we have demonstrated how a completely non-toxic intervention can effectively treat an aggressive cancer," said Valter Longo, the study senior author and the director of the USC Longevity Institute at the USC Leonard Davis School of Gerontology and professor of biological sciences at the USC Dornsife College of Letters, Arts and Sciences.

"We have taken two treatments that are studied extensively as interventions to delay ageing-- a fasting-mimicking diet and vitamin C -- and combined them as a powerful treatment for cancer," added Longo.

The researchers said that while fasting remains a challenging option for cancer patients, a safer, more feasible option is a low-calorie, plant-based diet that causes cells to respond as if the body were fasting.

Their findings suggest that a low-toxicity treatment of fasting-mimicking diet plus vitamin C has the potential to replace more toxic treatments.

Results of prior research on the cancer-fighting potential of vitamin C have been mixed. Recent studies, though, are beginning to show some efficacy, especially in combination with chemotherapy.

In this new study, the research team wanted to find out whether a fasting-mimicking diet could enhance the high-dose vitamin C tumour-fighting action by creating an environment that would be unsustainable for cancer cells but still safe for normal cells.

"Our first in vitro experiment showed remarkable effects. When used alone, fasting-mimicking diet or vitamin C alone reduced cancer cell growth and caused a minor increase in cancer cell death. But when used together, they had a dramatic effect, killing almost all cancerous cells," said Longo.

Longo and his colleagues detected this strong effect only in cancer cells that had a mutation that is regarded as one of the most challenging targets in cancer research.

These mutations in the KRAS gene signal the body is resisting most cancer-fighting treatments, and they reduce a patient's survival rate. KRAS mutations occur in approximately a quarter of all human cancers and are estimated to occur in up to half of all colorectal cancers.

The study also provided clues about why previous studies of vitamin C as a potential anticancer therapy showed limited efficacy. By itself, a vitamin C treatment appears to trigger the KRAS-mutated cells to protect cancer cells by increasing levels of ferritin, a protein that binds iron.

But by reducing levels of ferritin, the scientists managed to increase vitamin C's toxicity for the cancer cells. Amid this finding, the scientists also discovered that colorectal cancer patients with high levels of the iron-binding protein have a lower chance of survival.

"In this study, we observed how fasting-mimicking diet cycles are able to increase the effect of pharmacological doses of vitamin C against KRAS-mutated cancers," said Maira Di Tano, a study co-author at the IFOM, FIRC Institute of Molecular Oncology in Milan, Italy.

"This occurs through the regulation of the levels of iron and of the molecular mechanisms involved in oxidative stress. The results particularly pointed to a gene that regulates iron levels: heme-oxygenase-1," added Tano.

The research team's prior studies showed that fasting and a fasting-mimicking diet slow cancer's progression and make chemotherapy more effective in tumour cells while protecting normal cells from chemotherapy-associated side effects. The combination enhances the immune system's anti-tumour response in breast cancer and melanoma mouse models.

The scientists believe cancer will eventually be treated with low-toxicity drugs in a manner similar to how antibiotics are used to treat infections that kill particular bacteria, but which can be substituted by other drugs if the first is not effective.

To move toward that goal, they say they needed to first test two hypotheses: that their non-toxic combination interventions would work in mice, and that it would look promising for human clinical trials.

In this new study, they said that they've demonstrated both. At least five clinical trials, including one at USC on breast cancer and prostate cancer patients, are now investigating the effects of the fasting-mimicking diets in combination with different cancer-fighting drugs.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.